Prices – Talk Bio

Trump Administration Teases MFN Drug Pricing Rule as Commitment Deadline Looms for Companies

1 month ago talkbio0Tagged Commitment Deadline, direct-to-consumer sales, drug price, executive order, international reference price, Medicaid, MFN, Most-Favored-Nation, Parity, pharmaceutical manufacturers, Prices, Pricing, tariffs, Transplant Registry Unified Management Program

Trump administration; Most-Favored-Nation (MFN) pricing; drug pricing; executive order; pharmaceutical manufacturers; Medicaid; direct-to-consumer sales; price parity; commitment deadline; tariffs; international reference price

Bristol Myers Squibb to Launch Schizophrenia Drug Cobenfy in UK at US Price

1 month ago talkbio0Tagged Antipsychotic Agents, Cholinergic Receptors, Cobenfy, drug price, launch, Myers, Nance-Horan syndrome, Prices, Schizophrenia, squibb, U.S., UK

Bristol Myers Squibb; Cobenfy; schizophrenia; UK launch; drug pricing; US list price; NHS; cholinergic receptors; antipsychotic; 2026

Novo Nordisk’s Leadership Shakeup and Wider Implications; Ex-FDA Official Takes Regulatory Role at GSK

3 months ago talkbio0Tagged CEO, competition, Drops - Drug Form, drug market, Leadership, Maziar Mike Doustdar, Nordisk, Obesity, Prices, Regulatory Affairs, Shakeup, SmithKline Beecham, United States Food and Drug Administration

Novo Nordisk; leadership shakeup; new CEO; Maziar Mike Doustdar; share price drop; obesity drug market; competition; GSK; regulatory affairs; Former FDA

Replimune’s Shares Plunge After FDA Rejects Melanoma Drug Application

3 months ago talkbio0Tagged Antineoplastic Agents, Clinical Trial Design, Complete, Drops - Drug Form, Frequency of Responses, melanoma, Prices, Rejection, Replimune, Response Letter, RETINITIS PIGMENTOSA 1, United States Food and Drug Administration

Replimune; RP1; FDA rejection; melanoma; cancer drug; Complete Response Letter; clinical trial design; objective response rate; share price drop

FDA Commissioner Makary Proposes Fast-Track Drug Review Vouchers Tied to Lower US Prices, Without Detailing Criteria

4 months ago talkbio0Tagged drug price, fast-track approval, Makary, national priority review vouchers, Parity, pilot program, Prices, United States Food and Drug Administration

FDA; Makary; national priority review vouchers; drug pricing; fast-track approval; price parity; pilot program

Senate Drops Orphan Cures Act from Trump’s Tax Bill, Dealing Setback to Biopharma

4 months ago talkbio0Tagged Beak, Big Beautiful Bill, Biopharma, Drugs, Orphan, healthcare legislation, Infrequent, Ira (eukaryote), Mediation, Orphan Cures Act, Prices, reconciliation, Senate, Transplant Registry Unified Management Program

Orphan Cures Act; orphan drugs; Trump tax bill; biopharma; Senate; IRA price negotiations; rare diseases; Big Beautiful Bill; healthcare legislation; reconciliation bill